Welcome to LookChem.com Sign In|Join Free
  • or
5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

214706-53-3

Post Buying Request

214706-53-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

214706-53-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 214706-53-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,7,0 and 6 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 214706-53:
(8*2)+(7*1)+(6*4)+(5*7)+(4*0)+(3*6)+(2*5)+(1*3)=113
113 % 10 = 3
So 214706-53-3 is a valid CAS Registry Number.

214706-53-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-chloro-7-( 4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

1.2 Other means of identification

Product number -
Other names 5-chloro-7-(4-methyl-piperidin-1-yl)-6-(2,4,6-trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyrimidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:214706-53-3 SDS

214706-53-3Downstream Products

214706-53-3Relevant academic research and scientific papers

Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer's disease and related tauopathies

Kovalevich, Jane,Cornec, Anne-Sophie,Yao, Yuemang,James, Michael,Crowe, Alexander,Lee, Virginia M.-Y.,John, Trojanowski Q.,Smith, Amos B.,Ballatore, Carlo,Brunden, Kurt R.

, p. 432 - 450 (2016)

The microtubule (MT)-stabilizing protein tau disengages from MTs and forms intracellular inclusions known as neurofibrillary tangles in Alzheimer's disease and related tauopathies. Reduced tau binding to MTs in tauopathies may contribute to neuronal dysfunction through decreased MT stabilization and disrupted axonal transport. Thus, the introduction of brain-penetrant MTstabilizing compounds might normalize MT dynamics and axonal deficits in these disorders. We previously described a number of phenylpyrimidines and triazolopyrimidines (TPDs) that induce tubulin post-translational modifications indicative of MT stabilization. We now further characterize the biologic properties of these small molecules, and our results reveal that these compounds can be divided into two general classes based on the cellular response they evoke. One group composed of the phenylpyrimidines and several TPD examples showed a bell-shaped concentrationresponse effect on markers of MT stabilization in cellular assays. Moreover, these compounds induced proteasome-dependent degradation of a-and b-tubulin and caused altered MT morphology in both dividing cells and neuron cultures. In contrast, a second group comprising a subset of TPD molecules (TPD1) increased markers of stable MTs in a concentration-dependent manner in dividing cells and in neurons without affecting total tubulin levels or disrupting MT architecture. Moreover, an example TPD1 compound was shown to increase MTs in a neuron culture model with induced tau hyperphosphorylation and associated MT deficits. Several TPD1 compounds were shown to be both brain penetrant and orally bioavailable, and a TPD1 example increased MT stabilization in the mouse brain, making these compounds potential candidate therapeutics for neurodegenerative tauopathies such as Alzheimer's disease.

USE OF HYDROPHOBIN AS A SPREADING AGENT

-

, (2012/01/12)

The present invention relates to the use of hydrophobin as a spreading agent, in particular in cosmetic or pharmaceutical compositions. The invention further relates to compositions for treating surfaces, in particular cosmetic or pharmaceutical compositions for topical use, that contain hydrophobin as a spreading agent.

Fungicidal trifluorophenyl-triazolopyrimidines

-

, (2008/06/13)

The novel compounds of formula I: (R1, R2 and Hal are defined in the specification) show selective fungicidal activity. The new compounds are processed with carriers and adjuvants to fungicidal compositions.

Fungicidal trifluorophenyl-triazolopyrimidines

-

, (2008/06/13)

The novel compounds of formula I: (R1, R2 and Hal are defined in the specification) show selective fungicidal activity. The new compounds are processed with carriers and adjuvants to fungicidal compositions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 214706-53-3